Rituximab en el tratamiento de la granulomatosis eosinofílica con poliangitis

Muñoz, Sebastián Andrés; Gandino, Ignacio Javier; Orden, Alberto Omar; Allievi, Alberto

doi:10.1016/j.reuma.2014.08.005

Cited by 16 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients with FFS ≥2 or severe organ dysfunction (e.g., heart and central nervous system), intravenous cyclophosphamide plus intravenous high dose glucocorticoids (methylprednisolone 1000 mg for three days) have been proposed [34], [35], [36]. In refractory disease, the use of rituximab (anti-CD20 monoclonal antibody) [37], [38], [39], [40] and mepolizumab (anti-IL-5 monoclonal antibody) has been reported with success [41], [42], [43].…”

Section: Discussionmentioning

confidence: 99%

Eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome) as a differential diagnosis of hypereosinophilic syndromes

Santos

Silva²,

Lira

et al. 2017

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare systemic disease situated between primary small vessel vasculitides associated with antineutrophil cytoplasmic antibodies (ANCAs) and hypereosinophilic syndromes (HES). Here, we present a case of EGPA in a 38-year-old male, with a previous diagnosis of asthma, who presented with fever, migratory lung infiltrates and systemic eosinophilia that was refractory to previous courses of antibiotics. This case highlights the importance of the primary care physician understanding the differential diagnosis of pulmonary eosinophilic syndromes.

show abstract

Section: Discussionmentioning

confidence: 99%

Eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome) as a differential diagnosis of hypereosinophilic syndromes

Santos

Silva²,

Lira

et al. 2017

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

show abstract

“…Целью данного обзора стали адаптация для отечественного ревматологического сообщества и врачей различных других специальностей международных рекомендаций по диагностике и лечению ЭГПА и попытка расширения доказательной базы привлечением более поздних доступных публикаций [6][7][8][9][10].…”

Section: терапевтический архив 5 2016unclassified

“…В литературе содержатся разрозненные сообщения об использовании РТМ при ЭГПА. Так, в обзор доступных клинических наблюдений включены 27 пациентов с ЭГПА, из них 24 ответили на терапию РТМ, у 16 благодаря такому лечению достигнута ремиссия [7]. При этом частота достижения ремиссии при АНЦА-позитивном ЭГПА была выше, чем при АНЦА-негативном.…”

Section: терапевтический архив 5 2016unclassified

Current approaches to diagnosing and treating eosinophilic granulomatosis with polyangiitis: The 2015 international guidelines

Бекетова

Volkov

2016

Ter. arkh.

View full text Add to dashboard Cite

The 2015 international guidelines for the diagnosis and treatment of eosinophilic granulomatosis with polyangiitis, formerly known as the Churg-Strauss syndrome, are detailed and an attempt is made to expand an evidence base, by attracting more recent available publications. The new guidelines should not be regarded as final standards; these are primarily to extend the possibilities of choosing a personified management strategy for patients with eosinophilic granulomatosis with polyangiitis and to serve as the starting point for further in-depth investigations.

show abstract

“…Despite being a T cell mediated disease [ 3 ], humoral mechanisms might play a role in the pathogenesis of sarcoidosis [ 4 ]; moreover, B-cell-targeted therapies have been successfully used in autoimmune disorders in which T cells has been demonstrated to have a prominent pathogenetic role [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Rituximab in refractory sarcoidosis: a single centre experience

et al. 2015

View full text Add to dashboard Cite

Sarcoidosis is a granulomatous disease whose outcome varies from spontaneous remission to chronic refractory disease. Provided that steroids represent the gold standard as a first line treatment, many immune suppressants drugs are currently used in the disease management. However, refractory disease is still a great challenge. Rituximab is an anti-CD20 chimeric monoclonal antibody, currently used for the treatment of B cell malignancies and systemic autoimmune diseases. There are few case reports describing the successful use of Rituximab in refractory sarcoidosis with lung, eye, lymph nodes and skin involvement. In this paper we described three different case reports in which Rituximab has been used to treat refractory sarcoidosis and we reviewed the existing literature.

show abstract

Rituximab en el tratamiento de la granulomatosis eosinofílica con poliangitis

Cited by 16 publications

References 26 publications

Eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome) as a differential diagnosis of hypereosinophilic syndromes

Eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome) as a differential diagnosis of hypereosinophilic syndromes

Current approaches to diagnosing and treating eosinophilic granulomatosis with polyangiitis: The 2015 international guidelines

Rituximab in refractory sarcoidosis: a single centre experience

Contact Info

Product

Resources

About